Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Adverse events: hypotension · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher hypotension (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Dysphagia (WHO grade 3+) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Biperiden plus pilocarpine showed no clear difference in dysphagia (WHO grade 3+) compared with no treatment; GRADE not reported.
1 finding from 1 review
Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Insufficient evidence, from a single trial of 60 participants, to determine the effect on unstimulated salivary flow rate at the end of RT (Rode 1999; Analysis 2.1)
1 study · 60 participants
GRADE not reported
Oral mucositis (severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Death · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid leads to lower death compared with control (high certainty).
1 finding from 1 review
Disabling neurological deficit · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid showed no clear difference in disabling neurological deficit compared with control (low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Camomile showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Indigo wood root showed no clear difference in oral mucositis (moderate to severe) compared with saline (placebo); GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Intestinal trefoil factor showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Zinc sulphate led to lower oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Glutamine showed no clear difference in oral mucositis (any severity) compared with placebo/usual care; GRADE not reported.
1 finding from 1 review
RR 0.78 [0.57, 1.08]
5 studies
GRADE not reported
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).
1 finding from 1 review